Capricor Therapeutics, Inc.

NasdaqCM:CAPR Voorraadrapport

Marktkapitalisatie: US$846.6m

Capricor Therapeutics Beheer

Beheer criteriumcontroles 4/4

De CEO Capricor Therapeutics is Linda Marbán, benoemd in Jan2010, heeft een ambtstermijn van 14.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 747.32K, bestaande uit 29.5% salaris en 70.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.44% van de aandelen van het bedrijf, ter waarde $ 3.72M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 12.7 jaar en 11 jaar.

Belangrijke informatie

Linda Marbán

Algemeen directeur

US$747.3k

Totale compensatie

Percentage CEO-salaris29.5%
Dienstverband CEO14.8yrs
Eigendom CEO0.4%
Management gemiddelde ambtstermijn12.7yrs
Gemiddelde ambtstermijn bestuur11yrs

Recente managementupdates

Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up

May 08
Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up

Recent updates

Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Sep 18
Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Investors Don't See Light At End Of Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Tunnel

Jul 30
Investors Don't See Light At End Of Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Tunnel

Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up

May 08
Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up

Benign Growth For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Underpins Stock's 26% Plummet

Apr 19
Benign Growth For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Underpins Stock's 26% Plummet

We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate

Apr 16
We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate

Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip In Price Shows Sentiment Is Matching Revenues

Feb 03
Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip In Price Shows Sentiment Is Matching Revenues

Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth?

Dec 13
Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth?

Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation

Aug 13
Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation

A Look At The Fair Value Of Capricor Therapeutics, Inc. (NASDAQ:CAPR)

Nov 03
A Look At The Fair Value Of Capricor Therapeutics, Inc. (NASDAQ:CAPR)

Capricor Therapeutics GAAP EPS of -$0.29 misses by $0.03

Aug 10

Analyse CEO-vergoeding

Hoe is Linda Marbán's beloning veranderd ten opzichte van Capricor Therapeutics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

-US$34m

Jun 30 2024n/an/a

-US$28m

Mar 31 2024n/an/a

-US$24m

Dec 31 2023US$747kUS$221k

-US$22m

Sep 30 2023n/an/a

-US$29m

Jun 30 2023n/an/a

-US$29m

Mar 31 2023n/an/a

-US$29m

Dec 31 2022US$1mUS$210k

-US$29m

Sep 30 2022n/an/a

-US$27m

Jun 30 2022n/an/a

-US$25m

Mar 31 2022n/an/a

-US$23m

Dec 31 2021US$2mUS$200k

-US$20m

Sep 30 2021n/an/a

-US$18m

Jun 30 2021n/an/a

-US$18m

Mar 31 2021n/an/a

-US$17m

Dec 31 2020US$2mUS$150k

-US$14m

Sep 30 2020n/an/a

-US$11m

Jun 30 2020n/an/a

-US$9m

Mar 31 2020n/an/a

-US$7m

Dec 31 2019US$229kUS$157k

-US$8m

Sep 30 2019n/an/a

-US$9m

Jun 30 2019n/an/a

-US$12m

Mar 31 2019n/an/a

-US$14m

Dec 31 2018US$377kUS$233k

-US$15m

Sep 30 2018n/an/a

US$374k

Jun 30 2018n/an/a

US$2m

Mar 31 2018n/an/a

US$2m

Dec 31 2017US$602kUS$233k

US$2m

Compensatie versus markt: De totale vergoeding ($USD 747.32K ) Linda } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 3.17M ).

Compensatie versus inkomsten: De vergoeding van Linda is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Linda Marbán (61 yo)

14.8yrs

Tenure

US$747,315

Compensatie

Dr. Linda Marbán, Ph.D. Co-founded Capricor Therapeutics, Inc. (also known as Capricor, Inc). in 2005 and also has been its Chief Executive Officer since 2010 and serves as its President. Dr. Marbán has be...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Frank Litvack
Executive Chairman of the Board12.8yrsUS$759.55k0.29%
$ 2.5m
Linda Marbán
Co-Founder14.8yrsUS$747.32k0.44%
$ 3.7m
Anthony Bergmann
CFO & Corporate Treasurer6.8yrsUS$730.85k0.0052%
$ 44.4k
Karen Krasney
Executive VP12.7yrsUS$740.77k0.044%
$ 373.3k
Kristi A. Elliott
Chief Science Officerno datageen gegevensgeen gegevens
Catherine Kelleher
Consultantno datageen gegevensgeen gegevens

12.7yrs

Gemiddelde duur

64.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van CAPR is doorgewinterd en ervaren (gemiddelde ambtstermijn van 12.7 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Frank Litvack
Executive Chairman of the Board12.8yrsUS$759.55k0.29%
$ 2.5m
Linda Marbán
Co-Founder11yrsUS$747.32k0.44%
$ 3.7m
George Dunbar
Independent Director11yrsUS$211.13k0.023%
$ 196.6k
Earl Collier
Independent Director11yrsUS$222.37k0.13%
$ 1.1m
David Musket
Independent Director11yrsUS$237.36k0.20%
$ 1.7m
Francesco Muntoni
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Pat Furlong
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Eugenio Mercuri
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Craig McDonald
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Oscar Mayer
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Michelle Eagle
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Michael Taylor
Member of Scientific Advisory Board6.8yrsgeen gegevensgeen gegevens

11.0yrs

Gemiddelde duur

68yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van CAPR zijn ervaren en ervaren (gemiddelde ambtstermijn van 11 jaar).